Literature DB >> 11103165

Delivery of low molecular weight heparin for prophylaxis against deep vein thrombosis using a novel, needle-less injection device (J-Tip).

S J Hollingsworth1, K Hoque, D Linnard, D G Corry, S G Barker.   

Abstract

Given daily, low molecular weight (LMW) heparins are established for prophylaxis against deep vein thrombosis (DVT). We describe delivery by a novel, needle-less device that is virtually painless in action. Its use could provide benefits for patients in terms of comfort both psychologically and physically, and for healthcare workers in terms of safety from needle-stick injury. Patients undergoing elective surgery received LMW heparin delivered subcutaneously by either a standard needle and syringe or by the needle-less injection device, J-Tip. Pain was scored at the time of injection and plasma anti-factor Xa levels compared between the two methods of drug delivery 4 h later: 29 patients received LMW heparin delivered by the J-Tip and 31 patients by standard needle and syringe. The J-Tip was significantly more comfortable for the patient as the method of drug delivery (P < 0.001). When delivered by the J-Tip, LMW heparin was equally as efficacious, as plasma anti-factor Xa levels were similar for both methods of delivery (P < 0.42). In summary, delivery of LMW heparin by the J-Tip device was both comfortable and effective. These findings, taken in conjunction with its ease of use and complete freedom from risk of needle-stick injury might encourage further examination and use of this type of product.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103165      PMCID: PMC2503472     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  6 in total

1.  Needle-free vehicle for administration of radionuclide for sentinel-node biopsy.

Authors:  M R Keshtgar; S G Barker; P J Ell
Journal:  Lancet       Date:  1999-04-24       Impact factor: 79.321

2.  Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis.

Authors:  A Leizorovicz
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).

Authors:  K Andrassy; K Mörike; J Koderisch; E Weber
Journal:  Thromb Res       Date:  1988-03-15       Impact factor: 3.944

Review 4.  Low molecular weight heparin: a critical analysis of clinical trials.

Authors:  D Green; J Hirsh; J Heit; M Prins; B Davidson; A W Lensing
Journal:  Pharmacol Rev       Date:  1994-03       Impact factor: 25.468

Review 5.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

6.  Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).

Authors:  F Collignon; A Frydman; H Caplain; M L Ozoux; Y Le Roux; J Bouthier; J J Thébault
Journal:  Thromb Haemost       Date:  1995-04       Impact factor: 5.249

  6 in total
  3 in total

Review 1.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

2.  The Anesthetic Effectiveness of J-Tip Needle-Free Injection System Prior to Trigger Finger Injection: A Double-Blind Randomized Clinical Trial.

Authors:  Kushal R Patel; David Fralinger; Kyle J MacGillis; Joshua Wright-Chisem; Alfonso Mejia
Journal:  Hand (N Y)       Date:  2019-12-03

3.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.